1. SARS‐CoV‐2 infection in a X‐linked agammaglobulinemia adolescent: An immunological approach to treatment.
- Author
-
Stracuzzi, Marta, Vanetti, Claudia, Clerici, Mario, Zuccotti, Gian Vincenzo, Trabattoni, Daria, and Giacomet, Vania
- Subjects
- *
AGAMMAGLOBULINEMIA , *SARS-CoV-2 , *BRONCHIECTASIS , *MONONUCLEAR leukocytes , *BRUTON tyrosine kinase - Abstract
In acute SARS-CoV-2 infection, the administration of monoclonal antibodies and antiviral therapies was suggested, if humoral and T-cell-mediated immune responses are impaired, in order to prevent the risk of severe disease. An initial consideration, which is based on the lack of the NTA in acute infection and the observation that virus-specific memory T cell was only seen postinfection, is that the booster dose of COVID-19 vaccine was unable to trigger a relevant immunological protection in this patient. To the Editor, A very limited amount of data is present in the literature on SARS-CoV-2 infection in X-linked agammaglobulinemia (XLA) patients.[1] Moreover, it remains unclear the role of vaccination against SARS-CoV-2 in these subjects.[2] IL-6 is the main cause of the cytokine storm[3] that characterized severe COVID-19; notably, the lack of IL-6 production by macrophages due to the absence of Bruton tyrosine kinase (BTK) that characterized XLA patients was suggested to be responsible for the mild-to-moderate clinical course of infection seen in these patients.[4] Specific guidelines dealing with the particularities of treatment for COVID-19 in XLA patients are few and unclear. [Extracted from the article]
- Published
- 2023
- Full Text
- View/download PDF